Biotechnology

Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST PRS-060/AZD1402 first regulatory submission for global phase 2a study has been made; site initiation and patient screening expected this year PRS-343 in-use studies requested by FDA are completed; forthcoming meeting with FDA to align on path for continued development PRS-343 phase 1 monotherapy and atezolizumab combination data at ESMO...

Read more

Tetra Bio-Pharma Provides Update on Market Potential of ARDS-003

November 4, 2020 6:30 AM

Initial Drug Indication Targets COVID-19 Related Survival Benefits Cost-Saving Including When Used With a Remdesivir™ Standard of Care Expanded Post-Survival Indications (Reduce the Risk of Fibrosis and Multi-Organ Dysfunctions) Tetra Estimates Potential Revenues From Royalties on Net Sales, Milestone and Upfront Payments of Over $500 Million USD by 2026 OTTAWA, ON / ACCESSWIRE / November 4, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or...

Read more

Apollo Endosurgery to Present at November Investor Conferences

November 3, 2020 8:00 AM

AUSTIN, TX / ACCESSWIRE / November 3, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in two upcoming investor conference events during November 2020. November 17, 2020 Craig Hallum Alpha Select Investor Conference Apollo will participate in one on one meetings throughout the...

Read more

Edesa Biotech Achieves Enrollment Milestone in Dermatitis Study

November 3, 2020 7:25 AM

TORONTO, ON / ACCESSWIRE / November 3, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment of more than 50% of the patients planned for the first cohort of a Phase 2b clinical study evaluating the company's drug candidate as a monotherapy for chronic allergic contact dermatitis. The adaptive, double-blind study is evaluating the safety and efficacy of EB01...

Read more

Wuhan General Group Announces Medspresso & Handcrafted Delights Launch Event in Cape Town

November 2, 2020 9:30 AM

CAPE TOWN, SA / ACCESSWIRE / November 2, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update on its Medspresso and Handcrafted Delights brands: The Launch Announcement The launch of Medspresso and Handcrafted Delights will be celebrated November 7th, 2020 at our partner,...

Read more

Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

November 2, 2020 8:00 AM

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine. Under the TRANSVAC2 program, funded by the European Commission through the Horizon 2020 framework, Mymetics has started a preclinical study at the Helmholtz Center of Infection Research in...

Read more

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer(TM) Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

November 2, 2020 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / November 2, 2020 / Hillstream BioPharma, Inc. ("Hillstream", the "Company") today announced the second renewal of a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). The agreement enables NCATS's use of the company's Quatramer™ drug delivery technology. This technology will be used to develop...

Read more

Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

October 30, 2020 8:00 AM

The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s VANCOUVER, BC / ACCESSWIRE / October 30, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants...

Read more

Helix BioPharma Corp. Announced Fiscal 2020 Year-End Results

October 29, 2020 5:50 PM

RICHMOND HILL, ON / ACCESSWIRE / October 29, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its financial results for the 2020 fiscal year ended July 31, 2020. OVERVIEW The Company reported a consolidated net loss and total comprehensive loss...

Read more

Apollo Endosurgery, Inc. to Report Third Quarter 2020 Results on November 5, 2020

October 29, 2020 4:40 PM

AUSTIN, TX / ACCESSWIRE / October 29, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the third quarter ended September 30, 2020 on Thursday, November 5, 2020, after the U.S. stock markets close. Apollo will hold a conference call on Thursday, November 5,...

Read more

Dyadic to Report Third Quarter 2020 Financial Results on Thursday, November 12, 2020

October 29, 2020 4:30 PM

JUPITER, FL / ACCESSWIRE / October 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended September 30, 2020...

Read more

Wuhan General Group Updates on University of Pretoria Research Collaboration for Psilocybin Magic Mushroom Clinical Trials

October 29, 2020 11:10 AM

CAPE TOWN, SA / ACCESSWIRE / October 29, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following corporate update: The company's subsidiary MJ Medtech is pleased to announce it has formalized and executed a research collaboration and funding agreement with the University of Pretoria,...

Read more

Experion Reports Third Straight Quarter of Record Revenue Growth in Q3 and Reports on Financial and Operational Highlights

October 29, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / October 29, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), a cultivator and processor of premium cannabis products, is pleased to announce its financial results for its third quarter and for the period ended August 31, 2020. Jarrett Malnarich, CEO of Experion, stated, "This is our third consecutive quarter of sequential sales growth, which is a result of our...

Read more

Interim Management Statement Q3 2020 of Molecular Partners: Emergence of New Opportunities and Strong Platform Validation of DARPin® Therapeutics

October 29, 2020 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 29, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending September30, 2020. "Responding to the global COVID-19 pandemic requires an unprecedented effort on the part of therapeutics innovators like Molecular...

Read more

Applied UV, Inc. Announces Exclusive Licensing and Joint Development Agreement with Axis Lighting to Commercialize LED-based Technologies in UV-C Devices to Inactivate Pathogens on Surfaces in the Hospital Market

October 28, 2020 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / October 28, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of ultra violet C ("UV-C") light utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, today announced that its subsidiary, SteriLumen, Inc. ("SteriLumen"), and Axis Lighting, Inc. of Quebec, Canada, have entered into an exclusive...

Read more

Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery

October 28, 2020 8:30 AM

First CoreoGraft Recipient Discharged from the Hospital IRVINE, CA / ACCESSWIRE / October 28, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the first heart bypass surgery in HJLI's first-in-human CoreoGraft study was successfully completed and the patient has been discharged from the hospital. The protocol for the first-in-human study...

Read more

Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020

October 28, 2020 8:00 AM

BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate...

Read more

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

October 28, 2020 2:15 AM

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 MP0420 and MP0423 are potential medicines with a unique approach for both the prevention and treatment of COVID-19, with the possibility to manufacture at scale, easy administration and with the potential to bypass cold storage Molecular...

Read more

Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA

October 27, 2020 8:30 AM

Requests Pre-IDE Meeting with FDA IRVINE, CA / ACCESSWIRE / October 27, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration ("FDA") and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the VenoValve U.S....

Read more

Lexaria Bioscience Extends Warrant Term

October 26, 2020 2:30 PM

KELOWNA, BC / ACCESSWIRE / October 26, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in oral drug delivery platforms, has determined to extend the term of an aggregate 1,823,745 share purchase warrants (the "Warrants"), which were issued pursuant to a private placement of units. The Warrants were issued in two tranches pursuant to which 1,554,245 Warrants were issued on November 13,...

Read more